Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.1 (
ERK
)
95,504
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The genetic mechanisms underlying aortic stenosis (AS) and aortic insufficiency (AI) disease progression remain unclear. We hypothesized that normal aortic valves and those with AS or AI all exhibit unique transcriptional profiles. Normal control (NC) aortic valves were collected from non-matched donor hearts that were otherwise acceptable for transplantation (
n
= 5). Valves with AS or AI (
n
= 5, each) were collected from patients undergoing surgical aortic valve replacement. High-throughput sequencing of total RNA revealed 6438 differentially expressed genes (DEGs) for AS vs. NC, 4994 DEGs for AI vs. NC, and 2771 DEGs for AS vs. AI. Among 21 DEGs of interest,
APCDD1L
,
CDH6
,
COL10A1
,
HBB
,
IBSP
,
KRT14
,
PLEKHS1
,
PRSS35
, and
TDO2
were upregulated in both AS and AI compared to NC, whereas
ALDH1L1
,
EPHB1
,
GPX3
,
HIF3A
, and
KCNT1
were downregulated in both AS and AI (
p
< 0.05).
COL11A1
,
H19
,
HIF1A
,
KCNJ6
,
PRND
, and
SPP1
were upregulated only in AS, and
NPY
was downregulated only in AS (
p
< 0.05). The functional network for AS clustered around ion regulation, immune regulation, and lipid homeostasis, and that for AI clustered around ERK1/2 regulation. Overall, we report transcriptional profiling data for normal human aortic valves from non-matched donor hearts that were acceptable for transplantation and demonstrated that valves with AS and AI possess unique genetic signatures. These data create a roadmap for the development of novel therapeutics to treat AS and AI.
...
PMID:Transcriptional Profiling of Normal, Stenotic, and Regurgitant Human Aortic Valves. 3267 73